+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Recent Advances across T cell-based Therapeutics

  • ID: 4396914
  • Report
  • 15 pages
  • Frost & Sullivan
1 of 2

This edition of the Genetic Technology TOE depicts trends across T cell-based therapeutics. Novel T cell receptor-based therapeutic platforms and robust T cell target discovery platforms are profiled. The corresponding clinical trials scenario is also depicted, along with industry interactions.

The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions.

The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.

Note: Product cover images may vary from those shown
2 of 2

Innovations in T cell-based Therapies

  • Novel T cell Engager Platform for Targeting Malignant Cells
  • Using Dual-affinity Re-targeting for Cancer and Autoimmune Disease
  • Novel T cell Receptor (TCR)-based Therapeutic Platform
  • Robust T cell Target Discovery Platform

Clinical Trial Analysis and Industry Interactions

  • Summary of Key T cell-based Therapeutics in Clinical Studies
  • Summary of Key Contacts
Note: Product cover images may vary from those shown
3 of 2